Complications Associated With Transvenous Cardiac Implantable Electronic Devices: Recognition and Management
Annals of Internal Medicine · 2025
DOI: 10.7326/annals-25-02383 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of Internal Medicine, 2025. Verfasst von Peter J Zimetbaum und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston; and Richard A. and Susan F. Smith Center f…. Hauptthemen laut MEDLINE: Defibrillators, Implantable, Pacemaker, Artificial. Die Arbeit nennt 70 Literaturangaben.
Abstract (Originalsprache)
Cardiac implantable electronic devices (CIEDs) have increased the quality and duration of life for millions of patients. As their utilization continues to grow exponentially, clinicians need to diagnose and manage several device-associated complications that may arise during the CIED life cycle. This primer is tailored for the general internal medicine physician or hospitalist, who will inevitably take care of patients with CIEDs, to provide a contemporary update on the incidence and clinical manifestations of the 4 most common CIED complications, with the latest evidence to guide clinical management and expected outcomes. Specifically, this review focuses on: 1) generator/lead failure, which has decreased to less than 1% per year due to continuous advances in manufacturing and programming and is mostly managed conservatively with close monitoring; 2) CIED infections, which, while also rare at approximately 1% per year, carry a short-term mortality of 10% to 20%, thus requiring immediate diagnosis and often urgent treatment with lead extraction because antibiotic treatment is rarely effective; and 3) lead-related venous obstruction, which has highly variable incidence (5% to 30%) and manifestations, ranging from arm swelling to superior vena cava syndrome. Management options range from anticoagulation to balloon venoplasty, often with unsatisfying results. This review will also focus on 4) lead-related tricuspid regurgitation, which affects 20% to 30% of CIEDs and has become an area of intense interest with the development of percutaneous tricuspid treatments-where evidence is urgently needed to inform the need for lead extraction versus jailing during tricuspid interventions. The progressive adoption of leadless devices may significantly reduce many of these complications. Nonetheless, optimal management requires input from a multidisciplinary team of electrophysiologists and imaging, heart failure, and structural interventional specialists-who should be able to recognize and treat each complication promptly based on a rapidly evolving evidence base.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston; and Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center and Harvard…
- Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts (A.W.K.).
ORCID-Profile: Enrico G Ferro, Eric A Secemsky, Adolf W Karchmer
Zitieren
APA
Zimetbaum, P. J., Ferro, E. G., Secemsky, E. A., Karchmer, A. W., & Kramer, D. B. (2025). Complications Associated With Transvenous Cardiac Implantable Electronic Devices: Recognition and Management. Annals of Internal Medicine. https://doi.org/10.7326/annals-25-02383
Vancouver
Zimetbaum PJ, Ferro EG, Secemsky EA, Karchmer AW, Kramer DB. Complications Associated With Transvenous Cardiac Implantable Electronic Devices: Recognition and Management. Annals of Internal Medicine. 2025. doi:10.7326/annals-25-02383
BibTeX
@article{Zimetbaum2025,
author = {Zimetbaum, Peter J and Ferro, Enrico G and Secemsky, Eric A and Karchmer, Adolf W and Kramer, Daniel B},
title = {Complications Associated With Transvenous Cardiac Implantable Electronic Devices: Recognition and Management},
journal = {Annals of Internal Medicine},
year = {2025},
doi = {10.7326/annals-25-02383}
}
EUVIMED